<VariationArchive RecordType="classified" VariationID="3819" VariationName="NC_000014.9:g.87925163_87956828del" VariationType="Deletion" Accession="VCV000003819" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-10-15" DateCreated="2021-10-25" MostRecentSubmission="2021-10-25">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="18858" VariationID="3819">
      <GeneList>
        <Gene Symbol="GALC" FullName="galactosylceramidase" GeneID="2581" HGNC_ID="HGNC:4115" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>14q31.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="14" Accession="NC_000014.9" start="87933014" stop="87993667" display_start="87933014" display_stop="87993667" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="14" Accession="NC_000014.8" start="88399357" stop="88460008" display_start="88399357" display_stop="88460008" Strand="-" />
          </Location>
          <OMIM>606890</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000014.9:g.87925163_87956828del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>14q31</CytogeneticLocation>
      </Location>
      <OtherNameList>
        <Name>30-KB DEL, IVS10</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000014.9" sequenceAccession="NC_000014" sequenceVersion="9" change="g.87925163_87956828del" Assembly="GRCh38">
            <Expression>NC_000014.9:g.87925163_87956828del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="606890.0002" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff provided an HGVS expression for allelic variant 606890.0002 from the sequence of the breakpoint in Figure 2 of the paper by Rafi et al. , 1995 (PubMed 7581365).</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000014.9:g.87925163_87956828del AND Galactosylceramide beta-galactosidase deficiency" Accession="RCV000004023" Version="3">
        <ClassifiedConditionList TraitSetID="1051">
          <ClassifiedCondition DB="MedGen" ID="C0023521">Galactosylceramide beta-galactosidase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2010-12-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2010-12-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2021-10-25" MostRecentSubmission="2021-10-25">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20886637</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7581365</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8634707</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8940268</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9266397</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1051" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2446" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Krabbe leukodystrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leukodystrophy, Globoid Cell</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Globoid cell leukoencephalopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Galactosylceramide beta-galactosidase deficiency</ElementValue>
                <XRef ID="Krabbe+leukodystrophy/4044" DB="Genetic Alliance" />
                <XRef ID="192782005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Galactocerebrosidase deficiency</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">GCL</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">GLD</ElementValue>
                <XRef Type="MIM" ID="245200" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Krabbe disease comprises a spectrum ranging from infantile-onset disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) to later-onset disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). Although historically 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone have infantile-onset Krabbe disease and 10%-15% have later-onset Krabbe disease, the experience with newborn screening (NBS) suggests that the proportion of individuals with possible later-onset Krabbe disease is higher than previously thought. Infantile-onset Krabbe disease is characterized by normal development in the first few months followed by rapid severe neurologic deterioration; the average age of death is 24 months (range 8 months to 9 years). Later-onset Krabbe disease is much more variable in its presentation and disease course.</Attribute>
                <XRef ID="NBK1238" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6844" />
                <XRef ID="6844" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301416</ID>
                <ID Source="BookShelf">NBK1238</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AAP, 2021">
                <URL>https://publications.aap.org/pediatrics/article/148/3/e2021053126/181065/Leukodystrophies-in-Children-Diagnosis-Care-and</URL>
                <CitationText>Leukodystrophies in Children: Diagnosis, Care, and Treatment, Pediatrics (2021) 148 (3): e2021053126.</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Infantile.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, elevated psychosine, Krabbe Disease (infantile form), 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Krabbe disease: galactocerebrosidase deficiency, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Krabbe-Later-Onset.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased galactocerebrosidase, mildly elevated psychosine, Krabbe Disease (late-onset form), 2022</CitationText>
              </Citation>
              <XRef ID="487" DB="Orphanet" />
              <XRef ID="C0023521" DB="MedGen" />
              <XRef ID="MONDO:0009499" DB="MONDO" />
              <XRef Type="MIM" ID="245200" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="24189" SubmissionDate="2021-10-22" DateLastUpdated="2021-10-25" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="606890.0002_KRABBE DISEASE" title="GALC, 30-KB DEL, IVS10_KRABBE DISEASE" />
        <ClinVarAccession Accession="SCV000024189" DateUpdated="2021-10-25" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2010-12-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Rafi et al. (1995) analyzed the GALC gene in 2 patients with infantile Krabbe disease and identified homozygosity for a deletion of exons 11-17 that was found to be associated with a 502C-T transition on the same allele, which they designated '502/del.' The transition was later determined to be a polymorphism. Expression of the 502/del mutation in COS-1 cells resulted in no measurable GALC activity above that in mock-transfected cells. Rafi et al. (1995) studied an additional 46 patients with infantile Krabbe disease and identified 8 who were homozygous for the 502/del allele and 5 who were compound heterozygotes for 502/del allele and a second mutant allele. There were 21 patients who were heterozygous and 1 who was homozygous for the 502 polymorphism in whom the presence of the deletion could not be confirmed, but no patient was found with the deletion who did not carry the 502 polymorphism. Luzi et al. (1995) determined that the deletion is approximately 30 kb starting near the middle of intron 10 and including all of the coding region through exon 17 plus an additional 9 kb.</Attribute>
              <Citation>
                <ID Source="PubMed">7581365</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">8634707</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">De Gasperi et al. (1996) analyzed the GALC gene in 9 families with late-onset globoid cell leukoencephalopathy and in 1 patient with classic Krabbe disease and found that 5 of the patients were compound heterozygotes for the 30-kb deletion first reported by Rafi et al. (1995) and another mutation in the GALC gene.</Attribute>
              <Citation>
                <ID Source="PubMed">8940268</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">7581365</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Kleijer et al. (1997) found that the 30-kb deletion was present in 52% of mutant alleles from 41 Dutch patients with Krabbe disease.</Attribute>
              <Citation>
                <ID Source="PubMed">9266397</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Tappino et al. (2010) found the 30-kb deletion in 18% of disease alleles among their cohort of 30 Italian patients. They stated that the 502C-T transition has been renumbered as 550C-T based on the first ATG initiation codon as nucleotide +1.</Attribute>
              <Citation>
                <ID Source="PubMed">20886637</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GALC" />
          </GeneList>
          <Name>GALC, 30-KB DEL, IVS10</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">30-KB DEL, IVS10</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="606890.0002" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">KRABBE DISEASE</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="24189" TraitType="Disease" MappingType="Name" MappingValue="KRABBE DISEASE" MappingRef="Preferred">
        <MedGen CUI="C0023521" Name="Galactosylceramide beta-galactosidase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

